Bioverativ, the Biogen spin-off, has signed its first deal since it was formed in February 2017 with an agreement to acquire clinical-stage rare disease biotech, True North Therapeutics, for up to US$825 M. The deal includes True North’s Phase I candidate TNT009, a potential first-in-class treatment for cold agglutinin disease (CAD), which holds Orphan Drug Designation in both the USA and EU.